<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Hematological VitroScreen:


Champions' Hematological VitroScreen offers a quick, cost-effective solution to test your therapeutics in an ex vivo hematologic assay evaluating efficacy and mechanisms of action. 

This screen contains up to 30 unique primary Acute Myeloid Leukemia (AML) models that have been well characterized and feature patient responses, clinical annotation, NGS data (WES and RNASeq), proteomics, and phospho-proteomics datasets - available in Lumin. The Autologous AML platform, also available in this VitroScreen using the 15 model option, features a unique co-culture system containing primary patient AML cells and other immunologically relevant cells to drive responses to therapeutics.

Additionally, this screen includes the following rare and well-characterized models for other hematological indications: 10 Chronic Lymphocytic Leukemia (CLL) models, 8 Mantle Cell Lymphoma (MCL) models8 B Cell Acute Lymphoblastic Leukemia (B-ALL) models, 6 T Cell Acute Lymphoblastic Leukemia (T-ALL) models, 5 unique Multiple Myeloma (MM) models, and 6 Myelodysplastic Syndrome (MDS) & Chronic Myelomonocytic Leukemia (CMML) models.

Ex Vivo Hematologic Assay
Example Responses to Standard of Care Drugs
CTG-2406 (ALL) is responsive to doxorubicin, but not cytarabine. CTG-3950 (AML) responds to cytarabine and only responds moderately to venetoclax. CTG-3945 (CLL) responds to both ibrutinib and chlorambucil. CTG-3448 (MCL) responds to bortezomib and responds moderately to cytarabine. CTG-4200 (CMML)  responds to cytarabine and is resistant to venetoclax.
Examples of MM Model Response to Melphalan
Hematological Vitroscreen 19
CTG-4074, CTG-4075, and CTG-4076 show response to melphalan. MM  models are tested with only two SoC dose points due to the scarcity of the tumor sample. The dose points used are based on cell line assay results.
Example of Colony Forming Unit Assay 
AML model CTG-2456 shows a prevalence of CFU-GM. Treatment with Cytarabine at doses ≥10nM reduces the formation of these units. ATRA and 10% DMSO were used as positive controls.
Example of Comet Assay
AML model CTG-3950 shows extensive DNA damage (green tail) after treatment with cisplatin 1μM. Lower doses of cisplatin did not significantly increase DNA damage compared to negative control (0.1% DMSO).
Autologous AML VitroScreen: Flow Cytometry Analysis

Champions' Hematological VitroScreen includes:



Request More Information about the Hematological VitroScreen